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Application of sebomics for the 
analysis of residual skin surface 
components to detect potential 
biomarkers of type-1 diabetes 
mellitus
Satyajit S. Shetage1, Matthew J. Traynor1, Marc B. Brown1,2, Thomas M. Galliford3 &  
Robert P. Chilcott1
Metabolic imbalance in chronic diseases such as type-1 diabetes may lead to detectable perturbations 
in the molecular composition of residual skin surface components (RSSC). This study compared the 
accumulation rate and the composition of RSSC in type-1 diabetic patients with those in matched 
controls in order to identify potential biomarkers of the disease. Samples of RSSC were collected 
from the foreheads of type-1 diabetic (n = 55) and non-diabetic (n = 58) volunteers. Samples were 
subsequently analysed to identify individual components (sebomic analysis). There was no significant 
difference in the rate of accumulation of RSSC between type-1 diabetics and controls. In terms of 
molecular composition, 171 RSSC components were common to both groups, 27 were more common in 
non-diabetics and 18 were more common in type-1 diabetic patients. Statistically significant (P < 0.05) 
differences between diabetic and non-diabetic volunteers were observed in the recovered amounts of 
one diacylglyceride (m/z 594), six triacylglycerides (m/z 726–860) and six free fatty acids (m/z 271–345). 
These findings indicate that sebomic analysis can identify differences in the molecular composition of 
RSSC components between type-1 diabetic and non-diabetic individuals. Further work is required to 
determine the practical utility and identity of these potential biomarkers.
The human integument is coated with a thin layer comprising sebum, sweat, corneocyte debris and natural mois-
turising factors. Whilst generically referred to as sebum, the mixture is more accurately referred to as “residual 
skin surface components” or RSSC1.
Changes in the molecular composition of RSSC may arise as a result of local and/or systemic disease states2–4. 
Indeed, clinical conditions such as acne are associated with changes in both the secretion rate and the compo-
sition of sebum (Table 1). In addition, perturbations in the rate of sebum secretion have also been reported for 
hypothyroidism5, Turner syndrome6, Behçet’s syndrome7, Parkinson’s disease8 and rheumatoid arthritis7. Thus, 
the detection and quantification of disease-specific molecules present on the skin surface offer potential for the 
development of non-invasive diagnostic and prognostic techniques.
Decreases in sebum secretion rates have previously been reported for diabetes mellitus9, 10. However, to date 
there are no reports of specific biochemical changes in RSSC associated with chronic disease conditions such 
as type-1 diabetes. Thus, the aim of this human volunteer study was to identify any differences in the secretion 
rate or composition of RSSC between type-1 diabetic and non-diabetic volunteers. The rationale for specifically 
considering type-1 diabetic patients in the current study was related to the lack of insulin observed in these indi-
viduals11, 12. Decreased insulin levels may affect lipid synthesis in the sebaceous glands, as insulin is considered 
to be an essential hormone for the normal growth and differentiation of sebaceous gland cells13. A successful 
outcome to this pilot study would provide proof of principle, allowing the design of further studies to investigate 
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non-invasive biomarkers of type-1 diabetes present in RSSC that may have diagnostic or prognostic application. 
This study is novel in its approach to identifying diabetic patients based on skin lipid composition. Therefore, a 
broad method of analysis was required to allow for the detection of unknown lipid molecules and the identifica-
tion of potential biomarkers (which are subject to future confirmatory studies).
Results
Rate of RSSC accumulation. The rate of RSSC accumulation did not differ significantly (P > 0.05, Mann–
Whitney test) between type-1 diabetic (0.12 ± 0.06 mg cm−2, n = 55) and non-diabetic (0.13 ± 0.06 mg cm−2, 
n = 58) volunteers. There was no significant correlation (r2 = 0.004, P > 0.05, n = 51) between the amount of RSSC 
recovered and the clinically-confirmed duration of diabetes (data not shown). Blood concentrations of HbA1c in 
type-1 diabetic volunteers did not correlate (r2 = 0.001, P > 0.05, n = 54) significantly with the amount of RSSC 
recovered (data not shown).
Composition of RSSC. Analysis of RSSC by high-performance liquid chromatography (HPLC) with atmos-
pheric pressure chemical ionization (APCI) mass spectrometry (MS) presented complex chromatograms indicat-
ing the presence of several RSSC components. A representative chromatogram constructed using the normalised 
abundance of compound ions is shown in Fig. 1.
In total, 216 compound ions were consistently identified from samples of RSSC recovered from type-1 diabetic 
and non-diabetic participants: the majority (78%) were detected in positive ion mode, with the remainder (22%) 
in negative ion mode (Fig. 2).
There were 171 compound ions common to both type-1 diabetic and non-diabetic RSSC. The majority (145) 
were detected in LC-MS positive ionisation mode, with 26 detected in negative ionisation mode (Fig. 2). The 
normalised abundance of 2 of the 145 common positive ions identified as triglycerides was more than twofold 
higher (P < 0.05) in non-diabetic volunteers (Table 2). No significant difference (P > 0.05) was observed in the 
normalised abundance of the 26 common negative ions.
Twenty-two positive compound ions were consistently present only in the RSSC of non-diabetic volunteers 
(Fig. 2), of which five (1 diglyceride and 4 triglycerides) had a normalised abundance that was more than twofold 
higher (P < 0.05) than that of type-1 diabetic volunteers (Table 2). Two positive ion compounds were consist-
ently present only in type-1 diabetic volunteers. However, the normalised abundance of these compound ions 
did not differ significantly between the two groups (P > 0.05). In negative ionisation mode, five compound ions 
were consistently present only in RSSC recovered from non-diabetic volunteers (Fig. 2). No significant differ-
ence (P > 0.05) was observed in the normalised abundance of these five negative ions. A further 16 compound 
ions were consistently present only in the type-1 diabetic volunteers; the normalised abundance of six of these 
compound ions (all free fatty acids) was more than twofold higher (P < 0.05) than in non-diabetic volunteers 
(Table 3).
Discussion
This study identified a number of significant differences in the composition of RSSC recovered from type-1 dia-
betic and non-diabetic volunteers. In particular, there were significant perturbations in the frequency and abun-
dance of certain free fatty acids and (di and tri) glycerides. However, this study identified no diabetes-related 
effects in the rate of accumulation of RSSC. Moreover, the duration and severity (measured by HbA1c) of type-1 
diabetes also showed no correlation with the rate of accumulation of RSSC. Thus, there appear to be subtle differ-
ences in the composition but not the quantity of RSSC secreted by type-1 diabetic and non-diabetic individuals.
The rationale for specifically considering type-1 diabetic patients in the current study was related to the lack 
of insulin observed in these individuals11, 12. Decreased insulin levels in these individuals may affect lipid syn-
thesis in the sebaceous glands, as insulin is considered to be an essential hormone for the normal growth and 
differentiation of sebaceous gland cells13. A level of biomarker HbA1c ≥ 47.5 mmol mol−1 indicates the presence 
of diabetes14, 15. In clinically diagnosed diabetic patients, a level of HbA1c below 53.0 mmol mol−1 can be con-
sidered as good control of diabetes, whereas a level exceeding 53.0 mmol mol−1 is generally considered poor16. 
Non-physiological insulin profiles have been reported in patients with apparently well controlled diabetes17. 
Insulin is also known to affect the differentiation and proliferation of keratinocytes in rats13, 18 and it has been 
suggested that abnormal insulin signalling may also contribute to the dermal manifestations of diabetes19. In 
sebocytes, insulin exerts its effects through insulin-like growth factor-I receptors and upregulation of sterol reg-
ulatory element-binding proteins that, in turn, stimulate lipogenesis in sebocytes20. Insulin is also necessary for 
maximising the effect of growth hormone13. Given these multiple potential pathways through which abnormal 
insulin levels may affect sebum production, differences in sebum production between diabetic and non-diabetic 
Condition Observation Reference(s)
Acne
Increased sebum secretion rates 51–54
Decreased free fatty acid and increased triglyceride and wax ester 
content of sebum 52
Decreased concentrations of linoleic acid in skin surface lipids 
proportional to an increased rate of sebum production 55, 56
Table 1. Examples of clinical conditions that have been associated with changes in sebum secretion rate 
or sebum composition. Note that in this context, sebum is used as a generic term for residual skin surface 
components.
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Figure 1. Representative chromatogram of human residual skin surface components. Distributions were 
reconstructed based on the normalised abundance of compound ions detected in both positive and negative 
ionisation analysis (A) and negative ionisation analysis only (B); showing inset zoom-in) by high performance 
liquid chromatography with atmospheric pressure chemical ionization mass spectrometry.
Figure 2. Commonalities and differences in the number of compound ions detected in positive ionisation 
(bold) and negative ionisation (italics) mode between type-1 diabetic (n = 44) and non-diabetic (n = 58) 
residual skin surface component samples.
www.nature.com/scientificreports/
4SCienTifiC REPORTS | 7: 8999  | DOI:10.1038/s41598-017-09014-6
individuals would appear to be a physiological inevitability. The evidence from the studies cited above would tend 
to predict a decrease in sebum secretion in response to low levels of insulin.
This study built on previous work that showed a decrease in the rate of sebum secretion in diabetic rats21 and 
humans9, 21. One previous study9 measured casual sebum levels using the Sebumeter™ technique; however, a lim-
itation was the potential for sample-site contamination. In the present study, the subject’s forehead was cleaned 
before sample collection and protected for the duration of sample acquisition to ensure the measurement of RSSC 
accumulation was not unintentionally influenced by contamination of the measurement site, as per current rec-
ommendations and guidance21–25.
The results obtained in this study did not demonstrate any difference in the rate of accumulation of RSSC 
between type-1 diabetic and non-diabetic individuals, but did detect significant differences in composition. 
This is in agreement with a previous investigation that demonstrated no changes in the histological appear-
ance of sebaceous glands, although a decrease in triglyceride synthesis following the onset of diabetes has been 
reported in mice26. The treatment with exogenous insulin in type-1 diabetic patients may be responsible for the 
non-significant difference in the rate of RSSC accumulation between the two groups (although according to the 
HbA1c data, diabetes was not well controlled in the majority of the individuals).
The biomarker HbA1c is a form of haemoglobin modified by the non-enzymatic attachment of glucose. As 
the lifespan of an erythrocyte is normally around 120 days27, HbA1c reflects average plasma glucose levels over an 
eight- to twelve-week period28. Sebocyte differentiation and sebum production normally takes 21–25 days29 and 
so the HbA1c marker provides a good indication of blood glucose over several sebum production cycles. In the 
current study, no correlation was observed between HbA1c level and the rate of RSSC accumulation. This result 
is in alignment with the observations of Sakai et al.10 in human subjects. The lack of correlation between HbA1c 
and RSSC recovery may be explained by the fact that HbA1c represents the overall accumulation of excess glucose 
and so does not take into account the dynamic nature of blood glucose concentrations, which may stimulate or 
inhibit the rate of sebum production.
Compound ion 
(m/z_RT)
Normalised Abundance Mean (±standard error of 
the mean)
Putative Compound Identification (Name and formula)Non diabetic (n = 58) Type-1 diabetic (n = 44)
Not consistently present in Type-1 diabetic group
594.52_30.04 7.35 × 104 (1.28 × 104) 3.13 × 104 (1.06 × 104) DG(15:0_18:3) C36H64O5
726.59_27.60 1.63 × 105 (2.30 × 104) 7.96 × 104 (1.38 × 104) TG(13:0_13:0_15:0) C44H84O6
797.67_28.57 6.63 × 104 (1.11 × 104) 2.24 × 104 (4.85 × 103) TG(12:0_16:0_18:0) C49H94O6
844.71_29.28 5.34 × 104 (7.78 × 103) 1.42 × 104 (3.21 × 103) TG (16:0_17:2_17:2) C53H94O6
860.71_30.72 9.53 × 104 (1.27 × 104) 4.17 × 104 (9.61 × 103) TG(17:1_17:1_17:1) C54H98O6
Consistently present in both groups
762.62_27.22 1.75 × 105(2.73 × 104) 6.49 × 104 (1.00 × 104) TG(12:0_12:0_20:3) C47H84O6
776.62_27.64 1.03 × 105 (1.46 × 104) 5.02 × 104 (8.86 × 103) TG(15:1_15:1_15:1) C48H86O6
Table 2. Comparison of ion distributions in diabetics and non-diabetics (positive ionisation). Compound 
ions with significantly different normalised abundance (mean ± standard error of the mean) in positive ion 
chromatograms of non-diabetic (n = 58) and type-1 diabetic (n = 44) volunteers. Neutral mass of the putatively 
identified compounds was calculated by subtracting NH4+ adduct ion (m/z 18.033). Two triglycerides (TG) 
were consistently present in both groups. One diglyceride (DG) and four other triglycerides were consistently 
present only in the non-diabetic group. The normalised abundance of these seven compound ions was more 
than twofold higher (P < 0.05) in non-diabetic volunteers than in type-1 diabetic volunteers.
Compound 
ion (m/z_RT)
Normalised Abundance Mean ( ± standard 
error of the mean)
Putative Compound Identification (Name and formula)Non diabetic (n = 58) Type-1 diabetic (n = 44)
271.11_23.45 8.73 × 103 (1.35 × 103) 1.81 × 104 (1.63 × 103) FFA C13:1n-5 (8-tridecenoic acid) C13H24O2
273.12_23.45 2.98 × 103 (5.82 × 102) 9.37 × 103 (1.09 × 103) FFA C13:0 (Tridecylic acid) C13H24O2
313.15_7.661 2.72 × 104 (6.00 × 103) 7.42 × 104 (1.67 × 104) FFA C16:1n-14 (Gaidic acid) C16H30O2
315.11_10.10 6.05 × 103 (1.92 × 103) 2.48 × 104 (5.42 × 103) FFA C16:0 (Palmitic acid) C16H32O2
341.14_11.24 2.96 × 104 (6.21 × 103) 8.80 × 104 (1.73 × 104) FFA C18:1n-9 (Oleic acid) C18H34O2
345.07_23.45 1.73 × 103 (4.74 × 102) 2.26 × 104 (2.10 × 103) FFA C24:2n-15,19 (5,9-tetracosadienoic acid) C24H44O2
Table 3. Comparison of ion distributions in diabetics and non-diabetics (negative ionisation). Compound 
ions with significantly different normalised abundance (mean ± standard error of the mean) in negative 
ion chromatograms of non-diabetic (n = 58) and type-1 diabetic (n = 44) volunteers. Neutral mass of the 
putatively identified compounds was calculated by addition of OAc− adduct (m/z 59.01), except for compound 
345.07_23.45, which had the mass of H2O-H adduct (m/z 19.02) applied. All six free fatty acids (FFA) were 
consistently present in type-1 diabetic volunteers and their normalised abundance was more than twofold 
higher (P < 0.05) in type-1 diabetic volunteers than in non-diabetic volunteers.
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Sebomic analysis using LC-MS indicated that several components of RSSC were common to type-1 diabetic 
and non-diabetic volunteers. However, the normalised abundance of two common triglycerides was higher in 
non-diabetic volunteers (Table 2). In addition to these components, one diglyceride and four triglycerides showed 
a higher prevalence (as well as an increased abundance) in non-diabetic volunteers. Such variability in the com-
position of RSSC may partly be attributable to the availability of substrates for lipogenesis pathways. Sebaceous 
glands use various substrates for lipid synthesis, including lactate, acetate, amino acids and glucose30, 31. Sebaceous 
glands also contain elevated concentrations of glycogen30. Studies using radioactive glucose with isolated seba-
ceous glands have demonstrated that glucose is incorporated into all sebaceous lipid classes32. However, the rate of 
incorporation of glucose is approximately half that of lactate and acetate30. Using lactate and acetate as precursors, 
the rate of squalene and wax ester synthesis is significantly higher than with glucose, whereas triglyceride synthe-
sis is unaffected30. Lipids synthesised from glucose and lactate are very similar in composition33. Therefore, the 
effect of glucose on lipid synthesis could potentially alter RSSC composition, as postprandial hyperglycaemia and 
nocturnal hypoglycaemia are usually observed even in patients with well controlled type-1 diabetes34, 35. It is likely 
that diabetic patients use the same metabolic pathways of lipid synthesis as non-diabetics, but subtle differences 
in the availability of substrates for lipogenesis (caused by glucose imbalance) may introduce variability in the 
composition of sebum, which may explain the reduced abundance of diglycerides and triglycerides identified in 
the current study. Further work is required to investigate the effect of blood glucose concentrations on sebaceous 
gland activity in order to elucidate the mechanism through which glucose may influence the composition of skin 
surface lipids.
Interestingly, the abundance and prevalence of six fatty acids were greater in the diabetic group (Table 3), most 
probably as the result of increased lipase activity. Microbial lipase is responsible for the metabolism of triglycer-
ides, resulting in the release of free fatty acids on the skin surface36, 37. A greater number of micro-organisms have 
been isolated from the skin surface of diabetic compared with non-diabetic individuals38. Enhanced lipase activity 
as a consequence of increased microbial density on the skin of diabetic patients may, therefore, be responsible for 
the higher abundance of fatty acids in diabetic volunteers observed in the current study. In contrast, non-diabetic 
volunteers would be expected to have a higher abundance of triglycerides on the skin surface, due to a corre-
spondingly lower lipase activity: this was observed in the current study. A concurrent increase in diglyceride 
abundance (due to microbial hydrolysis of triglycerides) would also be expected in diabetic patients39. However, 
the only detectable change measured in this current study was a decrease in the normalised abundance of one 
diglyceride in diabetic patients (Table 2). This apparent anomaly cannot be explained without robust identifica-
tion of this component and further work is required to identify alternative routes of diglyceride synthesis that 
might explain this result.
Whilst it is tempting to speculate that the statistically significant differences in RSSC composition measured 
in this present study may provide a basis for developing a non-invasive, diagnostic indicator of type-1 diabetes, 
further work is clearly required to (1) confirm the identity of the compound ions that differ between diabetic and 
non-diabetic individuals, and (2) identify the mechanism(s) underpinning the compositional differences between 
the diabetic and non-diabetic groups. Prior to instigating the study, no information existed regarding whether 
or which skin lipids were indicative of a diabetic condition; therefore, we were obliged to adopt a broad method 
of analysis. This effectively precluded the use of specific internal standards and external reference samples from 
which we could confirm the exact identity of the biomarkers putatively identified in this pilot study. Such pilot 
studies are important in identifying new areas of research that may have future impact. Thus, preliminary studies 
such as ours need to adopt an inherently flexible methodology to allow the detection of unknown outcomes, 
which would otherwise be precluded by adopting a hypothesis-driven approach that might limit detection to 
“known” lipid molecules. Sebomic analysis of RSSC may represent a promising strategy for identifying biomark-
ers of other chronic diseases that are known to be associated with changes in sebaceous gland biochemistry. For 
example, the presence of phosphorylated tau protein in the cytoplasm of sebaceous glands and altered sebum 
secretion rates have been reported in Alzheimer’s40 and Parkinson’s disease8.
In conclusion, a comparison of RSSC collected from type-1 diabetic and non-diabetic volunteers did not show 
differences in the rate of RSSC accumulation. However, significant differences in the composition of RSSC were 
noted between type-1 diabetic and non-diabetic individuals. The observed variability in the RSSC composition 
of diabetic volunteers may be indicative of an altered availability of substrates for lipogenesis. However, bacterial 
lipase activity is also likely to be a contributory factor in the decreased recovery of triglycerides and correspond-
ing increase in free fatty acids observed in the RSSC of diabetic individuals. This study supports the feasibility of 
using RSSC as a non-invasive biomarker of type-1 diabetes.
Methods
This study was conducted in accordance with the principles of the Declaration of Helsinki and was independently 
approved by the NHS South Central–Hampshire A Research Ethics Committee.
Volunteers. Ethical approval to collect RSSC from non-diabetic volunteers was granted by the School of 
Pharmacy and Postgraduate Medicine Ethics Committee with Delegated Authority, University of Hertfordshire, 
Hatfield, UK (ethics approval number: PHAEC/10-25). For the collection of RSSC from type-1 diabetic 
patients, ethical approval was obtained from the National Research Ethics Service (NRES) Committee 
London-Bloomsbury (ethics approval number: 13/LO/1196). Collection of RSSC from non-diabetic volunteers 
was performed at the University of Hertfordshire (UK) while patients with clinically diagnosed type-1 diabetes 
were recruited at Watford General Hospital (UK) and Hemel Hempstead Hospital (UK). All volunteers partici-
pating in the study provided written informed consent. Demographic data were obtained using a questionnaire. 
Clinical information (e.g. duration of illness, glycated haemoglobin [HbA1c] blood concentrations, current 
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medication, etc.) was obtained from each type-1 diabetic patient’s hospital record. Patients in the type-1 diabetic 
group remained on exogenous insulin treatment throughout the experiment. Type-1 diabetic and non-diabetic 
groups were matched as far as possible for age and sex. Previous studies1, 41 have indicated that the rate of RSSC 
production is not affected by an individual’s ethnicity. Table 4 summarises the self-reported demographics of all 
participants.
Collection of RSSC. Collection of RSSC from volunteers was performed using a previously validated cig-
arette paper method1, 42 over a four-month period (February-June, 2014). Briefly, volunteers were allowed to 
acclimatise to the study room conditions (18–26 °C, 50–60% relative humidity) for at least 15 minutes before their 
forehead was cleaned with an isopropyl alcohol-based wipe (Fastaid™, Robinsons Healthcare, Worksop, UK) 
prior to the application of four pieces of dry, pre-weighed cigarette paper (previously washed with diethyl ether). 
Each paper was covered with a piece of aluminium foil which was fixed to the forehead using Micropore™ (3 M 
UK Plc., Bracknell, UK) adhesive tape. This assembly was held in place with an elastic head band. After removal 
from the forehead, the cigarette papers were dehydrated (by passive evaporative loss) in plastic sample cups cov-
ered with pierced Parafilm™ in a fume cupboard for a minimum period of two hours prior to storage at ambient 
temperature.
Analysis of RSSC. The rate of RSSC production was determined by gravimetric analysis performed 
using a 10-µg resolution fine balance (Mettler Toledo AX205; Mettler-Toledo Ltd., Leicester, UK) placed on a 
vibration-proof table. The balance was encased in a weighing cabinet (Bigneat Ltd., Hampshire, UK) to reduce 
draught artefacts. Each piece of cigarette paper was weighed before and after RSSC collection, the difference in 
weight being ascribed to RSSC recovered from the skin surface.
To identify compositional differences, RSSC present on the cigarette papers was extracted using hexane. The 
solvated RSSC samples were then dried by purging with nitrogen gas until all the hexane was visibly removed. 
The dried sample was then resuspended in 1 mL chloroform:methanol (2:1) using a roller mixer (Stirling mixer, 
Sandrest Ltd., Sussex, UK) for a minimum period of two hours. The sample was then transferred to a clean vial for 
LC-APCI-MS analysis. Chemical analysis was performed using a ThermoScientific™ Ultimate 3000 HPLC sys-
tem, comprising an RS 3000 quaternary pump, Ultimate 3000 RS auto-sampler and a column oven, connected to 
a ThermoScientific™ MSQ™ single quadrupole mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, 
UK). A reverse phase Zorbax SB C8 column (internal diameter 2.1 mm, length 150 mm, particle size 1.8 µm) was 
purchased from Agilent Technologies (Berkshire, UK) and used for chromatographic separation. The column was 
maintained at a temperature of 60 °C. The mobile phase was drawn from reservoirs containing 95:5 methanol:iso-
propyl alcohol (A) and 10 mM aqueous ammonium acetate (B). A gradient program was employed to optimise 
chromatographic separation: 0–1 min: 70% A; 20 min: 99% A; 45 min: 99% A; 55 min: 70% A; 60 min 70% A. The 
mobile phase flow rate was maintained at 0.25 mL min−1 throughout the 60-min run time. The APCI technique 
was used for ion generation (corona discharge 3 kV, probe temperature 400 °C, cone voltage 50 V). Ions were 
scanned in the range of 100 to 1000 Da to obtain a total ion scan in both positive and negative ionisation modes. 
ThermoScientific™ Chromeleon (version 3.8) software was used for the instrument control, data collection and 
initial data processing.
The data acquired for each sample were subsequently converted to “raw” file format and processed using 
Progenesis QI software (Nonlinear Dynamics, Newcastle Upon Tyne, UK). Spectral data alignment, peak detec-
tion (“peak picking”), background subtraction, normalisation and comparison of normalised abundance was 
performed using automated algorithms provided by the Progenesis QI software. Peak detection was performed 
on the intensity of compound ions, excluding events with a chromatographic (peak) width of less than 0.1 min. 
The abundance of compound ions in each sample was normalised against the abundance of compound ions in 
a reference chromatogram. An automated algorithm within the Progenesis QI software was used to select the 
most representative chromatogram among all the samples for use as a reference chromatogram. The final list of 
compound ion abundances was transformed using an inverse hyperbolic (arcsinh) function. The transformed 
data were then used to calculate any significant differences in the normalised abundance between groups. Such 
an “omics” approach is widely used in fields like metabolomics and proteomics for the processing of extremely 
complex biological data to enable a system level understanding of molecular interactions and dependencies in 
Analysis Total (n) Sex (n)
Age Ethnicity (n)
(years)* White Asian
Gravimetry
Type-1 diabetic (55)
Male (31) 39 ± 15 26 5
Female (24) 35 ± 14 23 1
Non-diabetic (58)
Male (25) 39 ± 15 19 6
Female (33) 38 ± 15 29 4
LC-APCI-MS
Type-1 diabetic (44)
Male (25) 36 ± 15 21 4
Female (19) 32 ± 13 18 1
Non-diabetic (58)
Male (25) 39 ± 15 19 6
Female (33) 38 ± 15 29 4
Table 4. Summary of residual skin surface component analysis, performed using gravimetry and liquid 
chromatography with atmospheric pressure chemical ionization mass spectrometry, in relation to volunteer 
details. *Data given as mean ± standard deviation.
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biological systems43–45. The prevalence of compound ions in each volunteer group was calculated as a percentage. 
A compound ion which was present in more than 75% of the population of a group was considered as a character-
istic feature of that group (referred to as a “consistent” compound ion). The 75% threshold was adopted from pre-
vious (proteomic and metabolomics) biomarker studies46–48. The normalised abundance of consistent compound 
ions was then compared between the type-1 diabetic and non-diabetic volunteers. Using the mass-to-charge 
ratio (m/z), the components of RSSC were putatively identified based on literature reports49 and lipid databases50, 
namely the LIPID Metabolites and Pathways Strategy (LIPID MAPS®) databases.
Statistical analysis. A commercially available software package (Statistical Package for the Social Sciences; 
SPSS Inc., Chicago, IL, USA, version 20) was used to perform the statistical analysis. The Kolmogorov–Smirnov 
test was used to determine the normality of the dataset and groups were compared by Mann–Whitney test. The 
transformed normalised abundance of compound ions detected in LC-APCI-MS analysis was compared by t-test 
using Progenesis QI software. A P-value < 0.05 was considered to be significant.
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